Sign In
Vertex Pharmaceuticals, Incorporated (VRTX)
SHARE
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Dr. Joshua S. Boger, Ph.D., Founder/CEO/President/Director
130 Waverly Street
Cambridge, MA 02139-4242
US
Map it 
Phone: (617) 444-6100
Fax: (617) 444-6680
Overview
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
Portfolio Articles
-
For Biotech, Hope and Money Spring Eternal
Despite a less-than-breathtaking number of biotech blockbusters to show for decades worth of investments, dealmakers continue to flock to the industry's big show.
Jan 09 2008
News Feeds
-
Biotech proves defensive against tough 2008 market
AP
Dec 31 2008
Press Releases
-
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences Nov-26-2008, 09:15AM EST
-
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences Nov-14-2008, 09:34AM EST
-
Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences Nov-06-2008, 04:32PM EST
News From Around the Web
News
-
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 27th Annual J.P. Morgan Healthcare Conference (PharmaLive)Jan 06 2009
-
Jan 05 2009
-
Good riddance (Boston Globe)Dec 26 2008
Employees
Number of Employees: 1,132
Revenue per Employee: $256,375
Financials
Quarterly
Annual
| Income Statement | 10/2008 | 08/2008 | 04/2008 | 02/2008 |
|---|---|---|---|---|
| Sales | 4.19 Mil. | 3.7 Mil. | 3.58 Mil. | -3.78 Mil. |
| Gross Operating Profit | 27.42 Mil. | 65.71 Mil. | 38.1 Mil. | 54.77 Mil. |
| Operating Income before D & A (EBITDA) | -129.74 Mil. | -90.31 Mil. | -98.11 Mil. | -84.02 Mil. |
| Total Income Before Interest Expenses (EBIT) | -129.16 Mil. | -91.32 Mil. | -96.15 Mil. | -85.75 Mil. |
| Total Net Income | -130.04 Mil. | -91.32 Mil. | -96.15 Mil. | -85.75 Mil. |
| Basic EPS, Total | -0.93 | -0.66 | -0.72 | -0.65 |
| Diluted EPS, Total | -0.93 | -0.66 | -0.72 | -0.65 |
| BALANCE STATEMENT | 10/2008 | 08/2008 | 04/2008 | 02/2008 |
|---|---|---|---|---|
| Cash and Equivalents | 920.07 Mil. | NA | 749.64 Mil. | 355.66 Mil. |
| Total Assets | NA | NA | NA | 496.85 Mil. |
| Total Liabilities | NA | NA | NA | 199.28 Mil. |
| Total Capitalization | 637.39 Mil. | NA | 591.76 Mil. | 271.3 Mil. |
| Cash Flow | 10/2008 | 08/2008 | 04/2008 | 02/2008 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | NA | NA | -252.48 Mil. |
| Net Cash From Investing Activities | NA | NA | NA | 405.17 Mil. |
| Net Cash From Financing Activities | NA | NA | NA | -10.19 Mil. |
| Net Change in Cash & Cash Equivalents | NA | NA | NA | 142.49 Mil. |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | -13.56 Mil. | -13.7 Mil. | -17.19 Mil. | -23.99 Mil. |
| Gross Operating Profit | 212.57 Mil. | 230.05 Mil. | 145.25 Mil. | 109.39 Mil. |
| Operating Income before D & A (EBITDA) | -385.21 Mil. | -199.52 Mil. | -147.28 Mil. | -124.92 Mil. |
| Total Income Before Interest Expenses (EBIT) | -388.99 Mil. | -199.98 Mil. | -186.09 Mil. | -147.93 Mil. |
| Total Net Income | -391.28 Mil. | -206.89 Mil. | -203.42 Mil. | -166.25 Mil. |
| Basic EPS, Total | -3.03 | -1.83 | -2.28 | -2.12 |
| Diluted EPS, Total | -3.03 | -1.83 | -2.28 | -2.12 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 355.66 Mil. | 213.17 Mil. | 78.04 Mil. | 55.01 Mil. |
| Total Assets | 496.85 Mil. | 771.41 Mil. | 385.06 Mil. | 406.71 Mil. |
| Total Liabilities | 199.28 Mil. | 251.01 Mil. | 100.24 Mil. | 153.74 Mil. |
| Total Capitalization | 271.3 Mil. | 525.93 Mil. | 419.27 Mil. | 370.44 Mil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | -252.48 Mil. | -22.48 Mil. | -172.05 Mil. | -142.16 Mil. |
| Net Cash From Investing Activities | 405.17 Mil. | -208.47 Mil. | -1.73 Mil. | 107.43 Mil. |
| Net Cash From Financing Activities | -10.19 Mil. | 365.86 Mil. | 197.46 Mil. | -8.63 Mil. |
| Net Change in Cash & Cash Equivalents | 142.49 Mil. | 135.13 Mil. | 23.04 Mil. | -43.15 Mil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
2.51 Bil.
2.44 Bil.
2.41 Bil.
3.13 Bil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.
RSS Most Read
Mobile